Skip to main content
. 2018 Jun 22;9(48):28903–28909. doi: 10.18632/oncotarget.25627

Figure 1. Swimmers plot of melanoma patients treated with low-dose ipilimumab and standard-dose pembrolizumab.

Figure 1

UM = uveal melanoma (N = 9), MUP = melanoma of unknown primary (N = 1), CM = cutaneous melanoma (N = 23), t-rAE = treatment-related adverse event, PD = progressive disease, SD = stable disease, PR = partial response, CR = complete response.